A phase 2 randomized controlled trial of luvadaxistat in treatment of adults with cognitive impairment associated with schizophrenia: results from the ERUDITE study
Open Access
- 24 April 2026
- journal article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 51 (11) , 2065-2073
Abstract
The phase 2 ERUDITE (NCT05182476) study evaluated the efficacy and safety of luvadaxistat, a selective ᴅ-amino acid oxidase inhibitor, for cognitive impairment associated with schizophrenia. ERUDITE was a randomized, double-blind, placebo-controlled, parallel-group study in adults with schizophrenia receiving background antipsychotic therapy. Following a 2-week placebo run-in, participants were randomized 2:1:1 to receive placebo, luvadaxistat 20 mg, or luvadaxistat 50 mg once daily for a 12-week treatment period. The primary endpoint was change from baseline to Day 98 in the Brief Assessment of Cognition in Schizophrenia (BACS) composite score. Safety outcomes included the incidence of treatment-emergent adverse events (TEAEs). Overall, 203 participants were randomized (placebo, n = 101; luvadaxistat 20 mg, n = 50; luvadaxistat 50 mg, n = 52), and 178 (87.7%) completed the treatment period. Luvadaxistat did not significantly improve performance (change from baseline) in BACS composite score versus placebo at Day 98 (least-squares mean difference [95% confidence interval]: 20 mg, –0.7 [–2.8, 1.4], p = 0.75; 50 mg, –0.5 [–2.7, 1.6], p = 0.69). TEAEs were reported in approximately one-third of participants across groups, with comparable rates observed between the luvadaxistat and placebo groups. TEAEs were mostly mild or moderate, and no safety concerns were identified. Luvadaxistat 20 mg or 50 mg did not show statistically significant changes in cognitive performance or functioning within the ERUDITE study. Trial registration: ClinicalTrials.gov identifier NCT05182476.Keywords
Funding Information
- Neurocrine Biosciences
This publication has 34 references indexed in Scilit:
- Finding the Right Dose: NMDA Receptor–Modulating Treatments for Cognitive and Plasticity Deficits in Schizophrenia and the Role of Pharmacodynamic Target EngagementBiological Psychiatry, 2024
- Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serineBiological Psychiatry, 2023
- Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on PsychosesJAMA Psychiatry, 2021
- P.166 Safety, pharmacokinetics, and pharmacodynamics of TAK-831, a selective d-amino acid oxidase inhibitor, in healthy volunteersEuropean Neuropsychopharmacology, 2019
- Why are there no approved treatments for cognitive impairment in schizophrenia?World Psychiatry, 2019
- Placebo Response and Practice Effects in Schizophrenia Cognition TrialsJAMA Psychiatry, 2017
- A systematic review comparing sex differences in cognitive function in schizophrenia and in rodent models for schizophrenia, implications for improved therapeutic strategiesNeuroscience & Biobehavioral Reviews, 2016
- Validation of a Computerized test of Functional CapacitySchizophrenia Research, 2016
- Circadian rhythms in cognitive functioning among patients with schizophrenia: Impact on signal detection in clinical trials of potential pro-cognitive therapiesSchizophrenia Research, 2014
- High dose D-serine in the treatment of schizophreniaSchizophrenia Research, 2010